Harsh parmar

Featured in: Favicon

medium.com Favicon

onclive.com

Articles

Highlighting the Key Takeaways From ASH 2024

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and minimal residual disease (MRD) monitoring are reshaping lymphoma treatment strategies, with emerging data showing promising outcomes for various lymphoma subtypes and ongoing trials exploring optimal sequencing of these therapies.
Treatment and Management of MM with Amyloidosis

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how insights from ASH 2024 are shaping the treatment and management of multiple myeloma (MM) with amyloidosis, emphasizing early diagnosis, novel therapies, and personalized treatment strategies to improve patient outcomes.
Recommendations For Future Clinical Trials in R/R MM

2 days ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

3 weeks ago | ajmc.com | Laura Joszt |Harsh parmar

While there is no cure for multiple myeloma, novel therapies are extending and saving lives, but they come at a price. Despite the promise of chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, stem cell transplantation remains the cornerstone treatment option for patients with multiple myeloma, explained Harsh Parmar, MD, associate professor of medicine, Hackensack University Medical Center.
Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

3 weeks ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how the 5-year follow-up data from the ZUMA-2 trial reveal sustained clinical benefit and durable responses for patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel, potentially reshaping treatment paradigms by demonstrating long-term efficacy of CAR T-cell therapy in a historically challenging hematologic malignancy.
Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

3 weeks ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s): , Panelists discuss how the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as presented in the phase 1/2 TRANSCEND CLL 004 study, may redefine treatment strategies by highlighting the potential benefits of combining chimeric antigen receptor (CAR) T-cell therapy with targeted agents and reshaping perspectives on sequential vs combination approaches...
Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

1 month ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

Author(s):,Panelists discuss how insights from the Liso-cel combined with ibrutinib (ibr) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL) are highlighted through the primary results of the open-label, phase 1/2 Transcend CLL 004 study.
Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

1 month ago | onclive.com | Andre Goy |Jamie Koprivnikar |Harsh parmar

OpinionVideoApril 24, 2025Author(s):,Panelists discuss how the preliminary results from the iMMagine-1 trial on anitocabtagene autoleucel (ASH 2024, abstract #1031) inform the real-world decision-making between bispecifics and chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM).